Applied Materials Income taxes receivable increased by 527.7% to $929.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 197.8%, from $312.00M to $929.00M. Over 5 years (FY 2020 to FY 2025), Income taxes receivable shows relatively stable performance with a -1.8% CAGR.
An increase may suggest overpayment or tax credits, while a decrease indicates the collection of refunds or application of credits against current liabilities.
This represents the amount of income tax overpayments or refundable credits owed to the company by government taxing aut...
Common across large-cap pharmaceutical firms, often fluctuating based on the timing of tax filings and audit settlements.
income_taxes_receivable| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $251.00M | $248.00M | $593.00M | $262.00M | $588.00M | $561.00M | $461.00M | $606.00M | $521.00M | $421.00M | $412.00M | $351.00M | $340.00M | $348.00M | $120.00M | $312.00M | $300.00M | $443.00M | $148.00M | $929.00M |
| QoQ Change | — | -1.2% | +139.1% | -55.8% | +124.4% | -4.6% | -17.8% | +31.5% | -14.0% | -19.2% | -2.1% | -14.8% | -3.1% | +2.4% | -65.5% | +160.0% | -3.8% | +47.7% | -66.6% | +527.7% |
| YoY Change | — | — | — | — | +134.3% | +126.2% | -22.3% | +131.3% | -11.4% | -25.0% | -10.6% | -42.1% | -34.7% | -17.3% | -70.9% | -11.1% | -11.8% | +27.3% | +23.3% | +197.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.